Background: Head and neck cancers are a heterogeneous group of malignancies, affecting various sites and subsites, with differing prognoses. The aim of this study was to analyse survival for European head and neck cancer patients in populations covered by population-based cancer registries (CRs), in relation to tumour subsite as prognostic factor.
original article Annals of Oncology aesthetic outcomes, while maintaining or improving survival for these cancers. The aims of the study were to analyse survival for head and neck cancers in the European populations covered by the population-based cancer registries (CRs) participating in EUROCARE-4, in relation to tumour subsite as prognostic factor and to assess the extent to which differences in subsite can account for survival differences between different European populations.
patients and methods
The analysis was confined to adults (age ‡15 years) diagnosed with malignant epithelial head and neck cancers diagnosed in 1995-1999 and followed up until 31 December 2003. We excluded adenocarcinomas and cases occurring after diagnosis of a previous malignancy (except nonmelanoma skin cancer) but included 1.5% of cases without histological verification. Most cases (94% of mouth and pharyngeal cancers and 86% of laryngeal cancers) were coded as squamous cell carcinoma (International Classification of Diseases for Oncology-3 8050-8084) [10] . Of the total of 51912 cancers considered, 15590 affected the larynx (C32.0-C32.9) and 36322 affected the mouth-pharynx, comprising base of tongue (C01.9), other and unspecified parts of tongue (C02), gum (C03), floor of mouth (C04), palate (C05), other and unspecified parts of mouth (C06), tonsil (C09), oropharynx (C10), pyriform sinus (C12.9), hypopharynx (C13), and other and ill-defined sites of lip, oral cavity and pharynx (C14). (Denmark, England, Iceland, Ireland, Malta, Norway, Sweden, Scotland, Wales, Northern Ireland, Slovenia and Slovakia) , the entire population is covered by cancer registration; the other countries are represented by regional CRs covering variable proportions of the national population (see footnote of Table 1 for details).
The CR selection criterion was that the proportion of not otherwise specified (NOS) cases should be inferior to 30% of the total: NOS laryngeal (C32.9) and NOS mouth-pharyngeal (02.9, C03.9, C06.9, C10.9, C13.9, C14.0 and C14.8) sites were considered separately as some registries had few NOS cases for mouth-pharynx but not for larynx, while the situation was reversed for other CRs. The choice of 30% was a trade-off between data quality and number of CRs included in the study.
statistical methods
Survival was expressed as relative survival, calculated as the ratio between the observed survival and the expected survival in the population of the same age, sex and country. Relative survival was estimated by the Hakulinen method [11] using estimates of population life tables for each registry area. 
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To account for differences in the age distribution of the different populations, relative survival was adjusted for age by the direct method using international cancer survival standard age distributions [12] .
Relative survival was modelled with a generalised linear model [13] , which assumes the hazards are constant within prespecified subintervals, and implies a Poisson distribution of the number of observed deaths in each interval. The models provide estimates of relative excess risks (RER) of death for each country considering age, sex and anatomic subsite as covariates, applied separately to mouth-pharyngeal and laryngeal sites. We also ran models providing estimates of RERs of death for each subsite (mouth-pharyngeal and laryngeal sites considered separately) with age, sex and country as covariates.
To estimate survival time trends, data from EUROCARE-3 (diagnosis period 1990-1994) and EUROCARE-4 (diagnosis period 1995-1999) were compared for CRs that provided data for both periods. Whisker plots was used to represent survival data over the two study periods. Stata software [14] was employed to carry out the analyses.
results Table 1 shows national coverage by site (mouth-pharynx and larynx), with percentages of cases known by death certificate only (DCO) and discovered at autopsy, percentages of histologically verified cases and percentages of cases alive with follow-up <5 years, as indicators of data quality. DCO/ autoptical cases were excluded from the survival analyses. Table  1 also shows men : women ratios.
For most countries, the percentage of histologically verified cases ranged between 97% and 100%. Lower percentages were found for Italy, Ireland and Slovakia for both sites; Northern Ireland for mouth-pharynx only and England and Scotland for larynx only.
The proportion of DCO/autoptical cases was high for Wales (6.5%) and Slovakia (6.2%) for mouth and pharynx; the percentage lost to follow-up was >6% only for the Czech Republic (mouth and pharynx) and Germany (larynx).
The male : female ratio was always >1 and was particularly high for France, Spain, Slovenia and Slovakia (>6 : 1 for mouth and pharynx and >10 : 1 for larynx); for larynx, the ratio was also very high for Italy (13 : 1) . Table 2 shows the number of cases by country with the percentages of cases for the principal anatomical sites and subsites. The percentage of tongue cancers originating from base of tongue (26% overall) was highest in France and Switzerland (>40%) and low in Norway, Sweden, England and Northern Ireland (<20%). Cancers of the tonsil (65% overall) accounted for >70% of all oropharyngeal cases in Northern Europe, the UK, Belgium and the Czech republic, whereas in Southern Europe, France and Slovakia, they accounted for <60%. Pyriform sinus cancers (55% overall) accounted for >70% of all hypopharyngeal cancers in France and The Netherlands but formed a low proportion of the total in several other countries, particularly Norway, Sweden, Germany and Glottic cancers accounted for 40%-60% of all laryngeal cancers in most countries, the exceptions being Iceland, Norway, Switzerland, The Netherlands (>60%), Spain and Slovakia (<40%).
Five-year age-standardised relative survival with 95% confidence intervals are presented by broad anatomical site and European region in Figure 1 . Northern Europe had the highest 5-year relative survival for tongue, oral cavity and oropharynx sites, whereas Southern and Central Europe had highest survival for hypopharynx and larynx sites. For all sites, survival was lower in Eastern Europe, significantly so for larynx, tongue and oral cavity. Table 3 shows 5-year age-standardised relative survival for the two main sites (mouth-pharynx and larynx) by sex and country. Survival was better for women in all countries except Northern Ireland for mouth-pharynx, whereas for larynx, this was only true for seven countries. Five-year age-standardised relative survival for mouth-pharynx ranged from 17% (Slovakia) to 49% (The Netherlands) for men and from 28% (Slovakia) to 61% (Germany) for women. Survival was better for larynx: rates ranged between 39% (Slovakia) and 78% (The Netherlands) for men and between 52% (Denmark) and 78% (Slovenia) for women. Thus, for both sites, survival was particularly low in Slovakia and high in The Netherlands.
Models estimating RERs of death are shown in Table 4 (mouth-pharynx) and Table 5 (larynx): Model 1 has age at diagnosis and sex as covariates; model 2 has age, sex and anatomical subsite as covariates. For mouth-pharynx (Table 4) , by model 1, Sweden and The Netherlands had significantly lower RERs of dying than England (reference), while Northern Ireland, Ireland, France, Slovenia, the Czech Republic and Slovakia had significantly higher RERs of dying than reference. After adjustment for anatomical subsite (model 2), RERs of dying for Italy and Germany became significantly lower than for England, whereas the RER for France was no longer significantly higher.
With regard to subsite, the RER of dying was highest for the postcricoid region (1.70) and lowest for cheek plus vestibule of mouth (0.53) compared with reference (base of tongue plus vallecula plus lingual tonsil).
For larynx (Table 5) , RERs of dying in Italy and The Netherlands were significantly lower than England; while Slovakia, France, Denmark, Ireland, Wales and Scotland had significantly higher RERs of dying than England (model 1). After adjustment for anatomical subsite (model 2), RERs remained high only for Slovakia, Ireland, Denmark and France. RERs of dying were higher than reference (glottis) for all anatomical subsites considered.
Analysing men and women separately (data not shown), we found that for most countries RERs were similar to those shown Table 4 (mouth-pharynx) for men and women together. However, for women alone, the differences in RERs of death between the Czech Republic, Ireland, Slovenia and England for mouth and pharynx were no longer evident. For larynx, RERs of death for men in Norway and Switzerland were significantly higher than that in England, while for The Netherlands, the RER was similar to reference. For women, RERs of death for larynx were similar to reference (England) for most countries except Italy (significantly lower) and Slovakia (significantly higher). Country-specific 5-year relative survival was greater in 1995-1999 than in 1990-1994 for larynx and slightly greater also for mouth and pharynx (Figure 2 ). Consistent with previous population-based findings [9] , the present study found that survival varied markedly with subsite. Thus, among mouth-pharynx sites, hypopharynx, base of tongue, lateral and posterior wall of the oropharynx (Table 4) were characterised by relatively poor survival, while among laryngeal sites, the supraglottic and subglottic subsites had poor survival (Table 5 ).
Since the distribution of subsites in European countries is not homogeneous, we expected the marked geographic differences in survival that we in fact found (Figure 1) . However, important survival differences persisted even after correcting for subsite distribution. In particular, considering mouth-pharynx subsites, age-and sex-adjusted RERs of death were similar in Norway, England, Scotland, Wales, Belgium, Germany, Switzerland, Italy and Spain, but significantly higher in Slovakia and the Czech Republic, and to a lesser extent also in Slovenia, France, Northern Ireland and Ireland (Table 4 , model 1). RERs of death continued to be significantly higher in these latter countries, except France, even after correcting for subsite distribution (Table 4 , model 2). We may, therefore, provisionally attribute poor survival in these latter countries to poor access to good treatment or late diagnosis.
Adjustment for subsite reduced RERs of death for most countries. Exceptions were the other UK countries, The Netherlands and Northern European countries-all characterised by lower frequencies of poor prognosis subsites (hypopharynx, base of tongue and oropharynx except tonsil). In France, where prognosis was fairly poor, subsite adjustment made the RER of death similar to that of England; in Italy and Germany, subsite adjustment made the prognosis significantly better than England.
Turning now to laryngeal sites, we note that most countries had similar prognoses after subsite adjustment. However, Slovakia, Denmark, Ireland and France continued to have significantly higher RERs of death than reference after subsite adjustment (Table 5 , model 2), again suggesting late diagnosis or poor access to good treatment in these countries. Nevertheless, RERs decreased following subsite adjustment in Slovakia and France (as well as in Spain, Germany, Slovenia, Scotland and Wales) also reflecting low frequencies of relatively good prognosis glottic cancers (compared with reference) in these countries (Table 2 ). 
Another possible reason for between-country differences in survival-even after subsite adjustment-is cancer site misclassification. Thus, possible misclassification of the good prognosis glottic site versus poor prognosis supraglottic, subglottic or NOS sites (Table 5) is suggested by the relatively high proportion of 'overlapping' sites, in turn probably reflecting the difficulty of identifying the primary subsite in the presence of locally advanced disease.
Other factors influencing survival in head and neck cancers are stage [15] , comorbidity [16] and patient socioeconomic status at least in the first 12-18 months following diagnosis [17] .
As regards stage, it is noteworthy that subsite determines the appearance of symptoms, which in turn influences stage at diagnosis [9] . As regards comorbidity, data suggest that this factor exerts its greatest effects on patients with good prognostic factors (tongue or glottic sites, early-stage disease and young age) [18] .
Socioeconomic status exerts its greatest effects on laryngeal cancers, where survival differences between deprived and affluent groups are greater than for any other common cancer [19, 20] . A study on survival trends for laryngeal sites in England and Wales found that the overall increase in 5-year survival between 1986-1990 and 1996-1999 occurred exclusively in the most affluent sector of the population [21] .
In the present study, we had no information on stage, comorbidity or socioeconomic status and no means to estimate the effect of confounding by misclassification. It is difficult, therefore, to account for all factors contributing to the survival differences for European head and neck cancer patients revealed by this study. Nevertheless, it is clear that differences in subsite distribution explain a considerable part of the survival differences, from which an important message emerges: survival comparisons require careful adjustment for anatomical subsite, so it is essential that CRs take steps to ensure that subsite information is accurate and complete.
Another important finding of this study is that 5-year relative survival increased from 1990-1994 to 1995-1999 for all types of head and neck cancer. These European results are encouraging because they are not mirrored by similar analysis conducted in the United States in particular for laryngeal cancer [22] . Finally, we note that survival differences between countries decreased from 1990-1994 to 1995-1999 , suggesting reductions in inequalities of treatment quality and treatment access across Europe. 
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